Diabetes management
made for you

Real-time monitoring. Proven results.^1-5 Empowered patients.

We look forward to meeting you at ATTD!

This year, learn about Dexcom continuous glucose monitoring (CGM) systems in a whole new way through a variety of interactive experiences at our booth.

Check out our new interactive booth

Explore our portfolio and partner network through two interactive stations

Engage with our experts at our exclusive in-booth presentations

Get a glimpse into the life of Dexcom Warriors and hear their stories

Add some fun to your day with coffee “made for you”

People viewing a in-booth presentation at the show

Dexcom in-booth presentations

Wednesday
19:15-19:35 - First Look at the G7 Patient Experience

Thursday
10:10-10:30 - First look at the Dexcom ONE User Experience
12:10-12:23 - Connection Series: Glooko and Novo Nordisk
12:25-12:40 - Connection Series: Tandem Diabetes
14:35-14:55 - 5 Ways to Use Clarity More Efficiently

Friday
10:10-10:30 - 5 Ways to Use Clarity More Efficiently
12:10-12:23 - Dexcom Connection Series: Ypsomed
12:25-12:40 - Dexcom Connection Series: Omnipod
14:35-14:55 - Clinical Application and Use of Dexcom CGM for Type 2 Diabetes

A presentation at one of the clinical sessions

Come to our clinical sessions

Hear exciting updates on CGM guidance and research, and learn the latest on all the ways Dexcom products can support the whole spectrum of diabetes patients. We have an action-packed agenda ahead! See our schedule below for a preview of presentation topics.

Dexcom clinical sessions

Thursday, 23 February /15:00–16:30 /Hall A6 + 7.

Symposium 1—Dexcom continues to lead in CGM technology across the diabetes spectrum

This is the first of 3 education programs sponsored by Dexcom, Inc. at ATTD 2023, titled “Dexcom Continues to Lead in CGM Technology Across the Diabetes Spectrum.” and moderated by Dr. Daniel Chernavvsky. This education program will focus on Dexcom CGM and its use with both our Type 1 and Type 2 diabetes patients. Real world experience and correlational outcomes of Dexcom G7 and its unique features will be shared by Dr. Emma Wilmot, as well as an introduction to the new 2GO-CGM study, focusing on the use of Dexcom CGM use in Type 2, intensive and non-intensive insulin treated patients by the primary investigator, Dr. Martin de Bock. Finally, the next generation Dexcom-TypeZero AID algorithm and first in-human study results will be presented by Drs. Stephen Patek, Enrique Campos-Nanez, Martin de Bock and Katharine Barnard-Kelly.

Leading the Way: The German Perspective

Leading the Way with Clinical Outcomes – The 7-Year COMISAIR Data

Leading the Way in Pregnancy Outcomes and Accuracy – The AiDAPT Study and G7 Accuracy in Pregnancy

Leading the Way in Real-World Outcome and New Innovative Technologies

Friday, 24 February /8:00–8:50 /Hall A3.

Symposium 2—Dexcom CGM: transforming the course of care for type 2 diabetes

This program reviews recently updated clinical practice guidelines on the use of RT-CGM in the management of type 2 diabetes. We will also present new data on the use of RT-CGM early in the course of care for type 2 diabetes. Additionally, we will examine how improving access for people with type 2 diabetes, on less intensive insulin regimens is positioned to impact utilization and adoption of RT-CGM in clinical practice. Hear from the experts regarding the ways to simplify the review of CGM data, specifically for type 2 diabetes, and steps that have been taken to integrate Dexcom Clarity data into electronic health records for more efficient clinical workflows.

Part 1: A global look at RT-CGM access and adoption in type 2 diabetes

Part 2: Are technology guidelines outpacing CGM adoption for type 2 diabetes in clinical practice?

Part 3: What to expect when people with type 2 diabetes are left to their own devices

Friday, 24 February /16:40–18:00 /Hall A5.

Symposium 3—Ahead of the curve: inpatient use of Dexcom G6 and automated insulin delivery systems

The emergence of diabetes technology in the hospital holds the potential to revolutionize glycemic management and change the standard of care. In this session, you’ll learn how these technologies are fueling the possibility in different patient populations and hospital settings. Our esteemed panel will discuss continuation of Dexcom RT-CGM upon hospital admission and an associated accuracy analysis in the pediatric population, preservation of intensive care unit capacity by using Dexcom G6 in a stepdown unit for patients admitted with diabetic ketoacidosis, feasibility of an automated insulin delivery system in patients with type 1 or type 2 diabetes in a medical-surgical unit, and perioperative use of fully closed-loop insulin delivery.

Part 1: Accuracy of Dexcom G6 in hospitalized children

Part 2: Preserving ICU capacity during the COVID-19 pandemic: using remote glucose monitoring in patients with diabetic ketoacidosis treated in the stepdown unit

Part 3: Automated insulin delivery for inpatients with dysglycemia (AIDING) feasibility study

Part 4: Fully closed-loop insulin delivery for perioperative glucose control

All presentations will be available on-demand after the conference on our free SIGMA platform and on the ATTD website.

Elevate diabetes care

Empower more people living with diabetes than ever before with Dexcom CGM systems. Explore our portfolio of products and discover how their unique features can support patients across the diabetes spectrum.

Product comparison

¹ Beck RW, et al. JAMA. 2017;317(4):371-378.
² Welsh JB, et al. J Diabetes Sci Technol. 2022. doi:10.1177/19322968221099879.
³ Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
⁴ Martens T, et al. JAMA. 2021;325(22):2262-2272.
⁵ Laffel L, et al. JAMA. 2020;323(23):2388-239

The sessions above are not included in the main conference CME/CPD credit.

.css-dwn86h{font-family:var(--chakra-fonts-body);font-size:1.25rem;font-weight:var(--chakra-fontWeights-normal);line-height:1.5rem;}@media screen and (min-width: 90em){.css-dwn86h{font-size:1.75rem;line-height:2rem;}}Real-time monitoring. Proven results.1-5 Empowered patients.